Every Form 4 that Marpai Inc (MRAI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MRAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRAI filings page.
Marpai, Inc. director Eitan Yaron reported equity compensation changes involving Class A Common Stock. On May 29, 2026, he acquired 175,000 shares at $0.00 per share as a grant or award, bringing his direct holdings to 1,224,073 shares.
A prior transaction on December 8, 2025 shows a disposition of 50,000 shares back to the issuer, described as a forfeiture of unvested restricted stock units under the award terms. The new RSUs were granted under Marpai, Inc.'s 2024 Global Stock Incentive Plan and are deemed fully vested on the issuance date, indicating compensation-related, non‑market activity.
Marpai, Inc. Chief Financial Officer Steve Andrew Johnson reported acquiring more Class A Common Stock. He made an open-market purchase of 1,100 shares at $0.62 per share and also received a grant of 125,000 restricted stock units under the company’s 2024 Global Stock Incentive Plan, which were fully vested on issuance. Following these transactions, he holds 1,024,192 shares directly, indicating a routine increase in his equity stake through both personal buying and equity compensation.
Marpai, Inc. director Shiv Sagiv reported stock-based compensation and a prior forfeiture involving Class A Common Stock. On May 29, 2026, he acquired 125,000 shares at $0.00 per share through a grant of fully vested restricted stock units under the 2024 Global Stock Incentive Plan. A prior December 8, 2025 entry shows a 50,000-share disposition to the issuer tied to the forfeiture of unvested RSUs. After these transactions, Sagiv directly holds 613,667 shares, and no derivative securities remain reported in this filing.
Marpai, Inc. director Robert M. Pons reported equity compensation and a prior forfeiture involving Class A Common Stock–linked awards. On May 29, 2026, he acquired 100,000 shares at a stated price of $0.00 per share as a grant or award. Footnotes explain these restricted stock units were granted under Marpai Inc.'s 2024 Global Stock Incentive Plan and are deemed fully vested on the issuance date. A prior transaction on December 8, 2025 shows a disposition of 50,000 shares back to the issuer, representing the forfeiture of unvested RSUs under the award terms. Following the reported transactions, Pons directly holds 484,200 shares of Class A Common Stock.
Marpai, Inc. director Jennifer Rosario Calabrese reported equity compensation changes in Class A common stock. On May 29, 2026, she acquired 100,000 shares at a stated price of $0.00 per share, reflecting a fully vested restricted stock unit award granted under Marpai Inc.'s 2024 Global Stock Incentive Plan. The filing also notes a December 8, 2025 forfeiture of 50,000 unvested RSUs returned to the issuer pursuant to the award terms. Following these transactions, she directly holds 225,000 shares of Class A common stock.
Lamendola Damien reported acquisition or exercise transactions in this Form 4 filing.
Marpai, Inc. reported that Chief Executive Officer Damien Lamendola received a grant of 300,000 shares of Class A common stock on May 29, 2026 at $0.00 per share. The shares were granted as restricted stock units under the 2024 Global Stock Incentive Plan and are deemed fully vested on the issuance date. Following the grant, he directly owns 1,650,000 Class A shares, with additional indirect holdings through entities he controls, including HillCour Investment Fund, LLC and WellEnterprises USA, LLC.
DiClaudio Colleen reported acquisition or exercise transactions in this Form 4 filing.
Marpai, Inc. director Colleen DiClaudio received 125,000 shares of Class A Common Stock as a fully vested equity award. The grant was made at a price of $0.00 per share under Marpai, Inc.'s 2024 Global Stock Incentive Plan and is deemed fully vested on the issuance date.
After this grant, DiClaudio directly holds a total of 267,500 shares of Class A Common Stock. This is a compensation-related stock award rather than an open-market purchase, so it reflects board-level equity compensation rather than a trading decision.
Marpai, Inc. director Eitan Yaron reported an open-market purchase of Class A Common Stock. On May 20, 2026, he bought 10,000 shares at a price of $0.27 per share. After this transaction, he directly holds 1,099,073 shares of Marpai stock.
SHIV SAGIV reported acquisition or exercise transactions in this Form 4 filing.
Marpai, Inc. director Shiv Sagiv received an equity grant of 100,000 shares of Class A Common Stock in the form of restricted stock units. The grant price is shown as $0.00 per share, indicating compensation rather than an open-market purchase.
According to the vesting terms, one-third of these RSUs vested on February 19, 2026, one-third vests upon execution of a Board-approved letter of intent or comparable indication of interest for a potential strategic transaction, and the final third vests upon the closing of that strategic transaction, in each case requiring continued service. After this award, Sagiv directly holds 522,000 shares of Marpai, Inc. common stock.
Marpai, Inc. (MRAI) director purchase disclosed. A director reported buying 100,000 shares of Class A common stock at $1.00 per share in a private placement on November 7, 2025, and received common warrants to purchase up to 200,000 additional shares at an exercise price of $1.00.
The warrants are exercisable immediately and remain exercisable until November 6, 2028. Following the transaction, the director directly owns 1,089,073 shares.
Marpai (MRAI) reported an insider transaction by a director. On 11/07/2025, the reporting person purchased 50,000 shares of Class A common stock at $1.00 per share and acquired common warrants for up to 100,000 shares with a $1.00 exercise price. The warrants are exercisable immediately and expire on 11/06/2028. Following the transaction, the insider beneficially owned 272,000 shares, held directly.
Marpai, Inc. (MRAI) insider transaction: Chief Operating Officer Dallas Scrip reported a private placement purchase on 11/07/2025 of 100,000 shares of Class A common stock at $1.00 per share and common warrants to purchase up to 200,000 additional shares. The warrants are exercisable immediately at $1.00 per share and remain exercisable for three years from the 11/07/2025 issuance date, expiring on 11/06/2028.
The securities are held indirectly by the Dallas S. Scrip and Michelle R. Script Trust, for which the reporting person and spouse serve as co‑trustees with shared voting and investment control.
Marpai, Inc. (MRAI) reported an insider purchase by director Robert Pons. On November 7, 2025, he bought 50,000 shares of Class A common stock in a private placement at $1.00 per share, together with common warrants to purchase up to 100,000 shares at an exercise price of $1.00.
The warrants are exercisable immediately and expire on November 6, 2028. Following the transaction, Pons beneficially owned 359,200 shares directly.
Marpai, Inc. (MRAI) CEO, Director, and 10% Owner Damien Lamendola reported acquiring 550,000 shares of Class A Common Stock on 10/20/2025 at $0, reflecting vested RSUs.
Following the transaction, he reported 1,350,000 shares held directly and indirect holdings of 6,419,893 shares through HillCour Investment Fund, LLC and 931,674 shares through WellEnterprises USA, LLC, as disclosed in footnotes.
Marpai, Inc. (MRAI) reported an insider equity award. A director acquired 75,000 Class A common shares on 10/20/2025 with a transaction code “A,” indicating an award or grant. The filing notes the shares came from RSUs that were deemed fully vested on the issuance date.
The reported acquisition price was $0.00. Following this transaction, the reporting person beneficially owns 222,000 shares, held directly. This filing records an equity compensation event and updates the insider’s holdings.
Marpai, Inc. (MRAI) — Director equity award
Director Yaron Eitan acquired 125,000 shares of Class A Common Stock on 10/20/2025 at a reported price of $0, reflecting settlement of RSUs that were deemed fully vested on the issuance date. Following the transaction, he beneficially owned 989,073 shares, held directly.
Marpai, Inc. (MRAI) reported an insider equity transaction. A director acquired 50,000 shares of Class A common stock on 10/20/2025 at a reported price of $0.00, reflecting settlement of RSUs that were deemed fully vested on the issuance date.
Following the transaction, the reporting person beneficially owns 175,000 shares, held directly. The filing was made on Form 4 and indicates the transaction type as an acquisition.
Marpai, Inc. (MRAI) reported an insider transaction on a Form 4. The Chief Financial Officer acquired 275,000 shares of Class A common stock on 10/20/2025 at $0, issued as RSUs that were fully vested on the issuance date. Following this award, the officer beneficially owns 898,092 shares, held directly.
Marpai, Inc. (MRAI) director Robert Pons reported equity awards on a Form 4. On 10/20/2025, he acquired an aggregate 225,000 Class A common shares via RSUs at $0: 50,000 RSUs deemed fully vested on issuance; 75,000 RSUs vesting over nine months (25,000 at each three‑month interval); and 100,000 RSUs with 50,000 vested on issuance and 50,000 vesting upon the Company’s uplisting to Nasdaq.
Following these transactions, beneficial ownership was 309,200 shares as of 10/20/2025. These entries reflect stock-based compensation mechanics and vesting conditions rather than open-market purchases.
Marpai, Inc. (MRAI) reported an insider equity award. A director acquired 75,000 shares of Class A common stock on 10/20/2025 at a reported price of $0, reflecting settlement of restricted stock units.
Following this transaction, the reporting person beneficially owns 142,500 shares, held directly. The filing adds that the RSUs were deemed fully vested on the issuance date, indicating immediate vesting and delivery of shares.
Marpai, Inc. (MRAI) — insider share sales reported. A reporting person filed a Form 4 showing open‑market sales of Common Shares on multiple dates: 10,000 shares at $1.43 on 08/13/2025; 20,000 at $1.40 on 08/15/2025; 20,000 at $1.40 on 08/18/2025; 20,000 at $1.40 on 08/19/2025; 10,000 at $1.42 on 08/20/2025; and 14,000 at $1.63 on 10/06/2025. Following the reported transactions, the filing lists 1,770,707 shares beneficially owned. The reporting person is indicated as a Director. Footnotes state the shares are held by IFCM MicroCap Fund LP, with Intelligent Fanatics Capital Management LLC as general partner; Mr. Cassel may be deemed a beneficial owner through shared voting and investment power and disclaims beneficial ownership except to the extent of his interests.
Marpai, Inc. (MRAI) director and CEO Damien Lamendola reported transactions dated 09/30/2025. He acquired 147,058 shares of Class A common stock at $1.36 per share and disposed of 800,000 shares on the same date. After these reported transactions, his beneficial ownership is stated as 6,419,893 shares, held indirectly through entities he controls as described in the footnotes. The filing shows two indirect holdings: shares held by HillCour Investment Fund, LLC (managed by Mr. Lamendola) and shares held by WellEnterprises USA, LLC, which is controlled through HillCour affiliates. The form is signed by Mr. Lamendola.
Marpai, Inc. director, Chief Executive Officer, and over-10% holder Damien Lamendola reported an indirect open‑market purchase of 896,903 shares of Class A common stock at an average price of $1.0592 per share. The shares are held by entities including HillCour Investment Fund, LLC and WellEnterprises USA, LLC, over which he holds voting and dispositive power. Following these transactions, his reported holdings include 6,272,835 indirect shares, 800,000 direct shares, and an additional 931,674 indirect shares of Class A common stock.
Marpai, Inc. (MRAI) director Shiv Sagiv amended a Form 4 to correct reported beneficial ownership after the vesting of restricted stock units (RSUs). The amendment shows 75,000 Class A common shares were acquired on 08/19/2025 through RSU vesting at no cash price, and the Reporting Person now beneficially owns 147,000 shares. The filing states the RSUs vested in three equal tranches of 25,000 shares at three, six and nine months after the grant date, and the amendment corrects an earlier filing that misstated the post-transaction ownership total.
Marpai, Inc. director Eitan Yaron received 75,000 restricted stock units (RSUs) that vested on a nine-month schedule and now beneficially owns 864,073 shares following the reported transactions. The RSUs vested in three tranches of 25,000 shares at three, six and nine months after grant, and the filing amends a prior Form 4 to correct the previously misstated post-transaction ownership total.
Marpai, Inc. (MRAI) director Eitan Yaron acquired 75,000 restricted stock units (RSUs) on 08/19/2025 under a grant that vests in three equal tranches over nine months. The filing reports these RSUs were recorded at $0 price and, after the grant, Mr. Yaron beneficially owns 1,542,527 shares. The Form 4 indicates the reporting person is a director and the transaction was a non-derivative acquisition of Class A common stock RSUs.
Marpai, Inc. director Shiv Sagiv reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025, increasing his beneficial ownership to 135,000 shares of Class A common stock. The filing indicates the RSUs were granted under a plan with a nine-month vesting schedule: 25,000 RSUs vested at three months, 25,000 at six months, and 25,000 at nine months.
The Form 4 was signed on 09/15/2025 and notes the transaction was made pursuant to a plan intended to meet the Rule 10b5-1 affirmative defense. Sagiv is identified as a director. No options or derivative transactions are reported in this filing.
Jennifer Calabrese, a director of Marpai, Inc. (MRAI), reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025. The Form 4 shows the 75,000 RSUs were acquired with a reported price of $0.00 and resulted in 125,000 shares of Class A common stock beneficially owned following the transaction. The filing indicates the transaction was made pursuant to a written plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions and that the RSUs vest over nine months in three equal tranches of 25,000 RSUs at three, six and nine months from the grant date.
The Form 4 was filed as an individual report and signed by Ms. Calabrese on 09/15/2025.